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Background. The presence of diabetes mellitus (DM) in
chronic hemodialysis (CHD) patients has potential to increase
body protein losses and muscle wasting.
Methods. In this study, we examined whole-body and skeletal
muscle protein metabolism in 6 CHD patients with type 2 (T2)
DM (2 male, 44.4 ± 6.1 years old, 2 white/4 African American
HbA1C = 9.5 ± 1.1%), and 6 non-DM CHD patients (2 male,
43.3 ± 6.7 years old, 2 white/4 African American) in a fasting
state, using a primed-constant infusion of L-(1-13C) leucine and
L-(ring-2H5) phenylalanine.
Results. CHD patients with T2DM had significantly increased
(83%) skeletal muscle protein breakdown (137 ± 27 vs. 75 ± 25
lg/100 mL/min). There was no significant difference in muscle
protein synthesis between groups (78 ± 27 vs. 66 ± 21 lg/100
mL/min, for DM and non-DM respectively), resulting in signif-
icantly more negative net protein balance in the muscle com-
partment in the DM group (−59 ± 4 vs. −9 ± 6 lg/100 mL/min,
P < 0.05). A similar trend was observed in whole-body protein
synthesis and breakdown. Plasma glucose levels were 113 ± 16
and 71 ± 2 mg/dL, P < 0.05, and insulin levels were 25.3 ± 9.6
and 7.3 ± 1.0 uU/mL, for DM versus non-DM, respectively, P <
0.05. No significant differences between DM and non-DM were
found in other metabolic hormones.
Conclusion. The results of this study demonstrate that CHD
patients with T2DM under a suboptimal metabolic control dis-
play accelerated muscle protein loss compared with a matched
group of non-DM CHD patients.
Over the last 2 decades, the proportion of end-stage re-
nal disease (ESRD) patients initiating chronic hemodial-
ysis (CHD) with a diagnosis of diabetes mellitus (DM)
has increased more than 3 times, reaching an alarming
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incidence of about 60% [1, 2]. CHD patients with DM
have the highest morbidity and mortality rates. They
also display increased incidence of body protein loss,
as assessed by low concentrations of serum biomark-
ers of nutritional status, when compared to CHD pa-
tients without DM [3]. Interestingly, the high prevalence
of protein depletion in CHD patients with DM seems
to be independent of its commonly recognized causes,
such as inadequate dialysis dose and insufficient protein
intake [3, 4].
Several studies have shown that there is increased pro-
tein breakdown in poorly controlled DM [4–9]. In insulin-
depleted type 1 diabetic patients, Biolo et al showed 30%
greater whole-body protein breakdown compared to con-
trols [10]. However, the impact of insulin resistance on
protein metabolism is less certain. While changes in pro-
tein breakdown due to insulin infusion in type 2 (T2) DM
patients have been demonstrated to be similar to that in
control subjects [9], synthesis of muscle proteins does not
appear to be responsive to insulin treatment [11].
Studies in ESRD patients suggest that at stable con-
ditions whole-body protein balance is preserved. On
the other hand, during stressful conditions such as se-
vere metabolic acidosis and the hemodialysis procedure,
there is significantly increased net protein breakdown.
While epidemiologic data suggest that diabetic ESRD
patients tend to have worse nutritional status compared
to nondiabetic ESRD patients, it is not clear if DM
alone and/or in combination with uremia-related factors
would act synergistically to promote whole-body or skele-
tal muscle protein breakdown. In order to explore the
mechanism(s) by which CHD patients with T2DM are
predisposed to increased protein depletion, we studied
6 CHD patients without DM and 6 CHD patients with
DM matched for age, gender, and race in a fasting state,
using primed-constant infusion of L-(1-13C) leucine and
L-(ring-2H5) phenylalanine. T2DM subjects were stud-
ied during glycemic and insulinemic states that were not
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necessarily optimally controlled, but rather with the in-
sulin regimens maintained at the discretion of their physi-
cian.
METHODS
Patients
Patients were recruited from the Vanderbilt Univer-
sity Outpatient Dialysis Unit. Inclusion criteria for the
study included patients who had been on CHD therapy
for at least 6 months, with less than 100 mL/min of urine
output, using a biocompatible hemodialysis membrane
(Fresenius F80, Fresenius USA, Lexington, MA, USA),
receiving an adequate dose of dialysis (double pool Kt/V
≥1.4), on a thrice-weekly CHD program, for 6 to 108
months (median 24 months). Patients with active in-
fectious or inflammatory disease (i.e., vascular access
infections and overt periodontal disease), patients hos-
pitalized within the last 3 months prior to the study, pa-
tients with recirculation in the vascular access and/or vas-
cular access blood flow less than 750 mL/min detected on
the arterioveous (AV) shunt, and those receiving steroids
and/or immunosuppressive agents were excluded from
the study. The Institutional Review Board of Vanderbilt
University approved the study protocol and written in-
formed consent was obtained from all study patients. Pa-
tient characteristics are shown in Table 1.
Design
After reviewing the inclusion and exclusion criteria,
6 CHD patients with T2DM were recruited and stud-
ied along with 6 age-, gender-, and race-matched nondia-
betic CHD patients. Presence of DM was determined by
the American Diabetes Association guidelines [12], by
one of the following: (1) Symptoms of diabetes plus ca-
sual plasma glucose concentration equal or greater than
200 mg/dL (11.1 mmol/L), where casual is defined as any
time of day without regard to time since last meal. The
classic symptoms of diabetes include polyuria, polydipsia,
and unexplained weight loss. (2) Fasting plasma glucose
levels greater than 126 mg/dL (7.0 mmol/L). Fasting is
defined as no caloric intake for at least 8 hours. (3) A
2-hour postload glucose level greater than 200 mg/dL
(11.1 mmol/L) during an oral glucose tolerance test. The
test should be performed as described by the World
Health Organization (WHO), using a glucose load con-
taining the equivalent of 75 g anhydrous glucose dissolved
in water.
Five out the 6 patients with T2DM required insulin
administration, and 1 was maintained on a low carbo-
hydrate diet as the glucose-lowering treatment. Insulin
treatments were designed to bring fasting plasma glucose
between 90 and 120 mg/dL. Long-acting insulin was
maintained at regular regimen for all study patients.
Table 1. Demographic, nutritional characteristics, and biochemical
parameters of the study population (N = 6)
Demographics DM Non-DM
Gender M/F 2/4 2/4
Race (White/Black) 2/4 2/4
Age years 44.4 ± 2.5 43.3 ± 6.7
Etiology of ESRD 3 Type 2 DM 4 HTN
2 HTN 2 ADPKD
1 Sickle cell
Body composition DM Non-DM
BMI kg/m2 32.1 ± 3.2 22.7 ± 1.4
Body weight kg 92.8 ± 7.4 64.8 ± 5.6a
Fat mass by DEXA kg 39.1 ± 5.8 16.9 ± 3.3a
Fat-free mass by DEXA kg 53.7 ± 5.0 47.9 ± 5.8
Laboratory values
Serum albumin g/dL 3.33 ± 0.1 3.37 ± 0.2
Serum prealbumin mg/dL 32.3 ± 5.9 32.2 ± 3.9
Serum creatinine mg/dL 9.2 ± 1.0 9.8 ± 1.2
Serum transferrin mg/dL 163 ± 15 150 ± 17
Blood urea nitrogen mg/dL 55.2 ± 5.2 47.5 ± 5.8
Serum CRP mg/dL 0.87 ± 0.6 0.53 ± 0.2
(0.3; 0.3–3.7) (0.3; 0.3–1.3)
Plasma glucose mg/dL 113 ± 16 71 ± 2a
Plasma c-peptide ng/mL 4.0 ± 0.7 6.6 ± 1.3
HbA1C% 9.5 ± 1.1 N/A
HOMA-R 2.92 ± 0.13 1.38 ± 0.17a
Hemoglobin g/dL 11.8 ± 0.6 12.5 ± 1.1
Plasma bicarbonate mg/dL 25.3 ± 0.9 26.3 ± 1.1
Abbreviations are: M, male; F, female; ESRD, end-stage renal disease;
ADPKD, autosomal dominant polycystic kidney disease; DEXA, dual-energy x-
ray absorptiometry; CRP, C-reactive protein; HbA1C, glycosylated hemoglobin;
N/A, not available; HOMA-R, homeostasis model assessment. Values are
absolute numbers and percentage or mean ± SEM for each study group (DM
and non-DM), except for serum CRP (mean, SEM, median, and range).
aDenotes significant difference vs. T2DM.
The study subjects received their maintenance dose
long-acting insulin as prescribed at the outpatient set-
ting (15 units, 18 units, 20 units, 50 units for 4 sub-
jects and 20 units twice a day for 1 subject). Any ad-
ditional short-acting insulin was withheld after the last
meal prior to the study. Estimation of insulin resistance
was performed by the homeostasis assessment model
(HOMA-R), as follows: [plasma insulin (lU/mL) ×
plasma glucose (mmol/L)]/22.5. Within a week prior to
each study, dual-energy x-ray absorptiometry (DEXA)
was performed to estimate lean and fat body masses,
and resting metabolic rate was measured via indirect
calorimetry to establish energy requirements prior to ex-
perimentation. Patients were admitted to the General
Clinical Research Center (GCRC) at approximately 7 PM
on a nondialysis day, received a balanced meal from the
GCRC bionutrition service, and remained fasting after
that.
A schematic diagram of the metabolic study day proto-
col is depicted in Figure 1. Each metabolic study consisted
of a 2-hour equilibration phase followed by a 1-hour sam-
pling phase. A dialysis catheter was placed at the venous
site of the AV shunt of the forearm at 8 AM to collect
a baseline blood sample (to assess baseline biochemical
nutritional markers and isotopic backgrounds) and then
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Fig. 1. Schematic diagram of the metabolic study day protocol. Ar-
rowheads denote time points for blood draws and breath sample col-
lections. Metabolic cart and plethysmography measurements were per-
formed once during the equilibration phase. A primed-constant infusion
of L-(1-13C) leucine and L-(ring-2H5) phenylalanine was maintained
throughout the entire study (360 min).
to initiate the isotope infusion. The arterial side of the
AV shunt was the site of choice used for sampling arte-
rial blood. The only occasion that would affect the arte-
rial purity of the samples would be if there were stenoses
in the AV shunt, causing the venous blood to mix with
arterial blood (recirculation). Therefore, recirculation of
the AV shunt as well as vascular access blood flow to
assess stenoses in the AV shunts was checked in every
patient prior to each study utilizing the ultrasound di-
lution technique (Transonic Systems, Inc., Ithaca, NY,
USA). The venous site of the AV shunt was used to
infuse the isotopes. Another catheter was placed in a
deep vein (on a retrograde insertion) of the contralat-
eral forearm to sample blood draining from the fore-
arm muscle bed. At the start of the infusion, subjects
received a bolus injection of NaH13CO3 (0.12 mg/kg), L-
(1-13C) leucine (7.2 lmol/kg), and L- (ring-2H5) pheny-
lalanine (7.2 lmol/kg) to prime the CO2, leucine, and
phenylalanine pools, respectively. A continuous infusion
of leucine (0.12 lmol/kg/min) and phenylalanine (0.12
lmol/kg/min) isotopes was then started and continued
throughout the remainder of the study.
Simultaneously with each blood sampling, breath sam-
ples were collected from the subjects via a Douglas bag
with duplicate 20 mL samples placed into nonsiliconized
glass vacutainer tubes for measurement of breath 13CO2
enrichment. Subjects were asked to breathe through
a mask for 1 minute each time blood was collected.
Forearm blood flow was estimated using capacitance
plethysmography (Model 2560 with URI/CP software
version 3.0; Moro Bay, CA, USA) during the equilibra-
tion phase. Specifically, 2 blood pressure cuffs were placed
on the subject’s forearm contralateral to the forearm with
the AV shunt: 1 cuff 3 cm above the antecubital fossa and
another cuff on the wrist. The technique involves abrupt
interruption of venous outflow with a proximal cuff in-
flated to above venous pressure, but below arterial pres-
sure (approximately 50 mm Hg), which causes the volume
of the limb to increase due to arterial inflow. A mercury
strain gauge plethysmograph is used to measure the vol-
ume change in the limb. The rate of change of the volume,
in percent per minute, is the arterial flow rate at the mo-
ment of venous occlusion. This procedure was repeated
for at least 5 times or until 5 similar measurements were
obtained. Energy expenditure and respiratory quotient
were also determined during the equilibration period by
indirect calorimetry using a metabolic cart (Sensormedics
2900; Palo Alto, CA, USA) to measure ventilation rates,
CO2 production, and O2 consumption. Metabolic cart
measurements were performed for a period of 20 to
30 minutes. Patients had been resting in bed for at least
1 hour before measurements, and were instructed to stay
still, breath normally, and not to talk during the mea-
surement. All study patients had been acclimated to the
metabolic cart procedure within a week before the study,
as described earlier. In addition, we allowed the initial 5
to 10 minutes of measurements on the study day for addi-
tional acclimation and stability of oxygen consumption,
and averaged measurements thereafter to obtain a single
value for each patient. Simultaneous blood and breath
samples were collected once prior to the start of the study
and 5 times during the sampling phase. Once the study
was finished, patients were given a meal, received their
usual hemodialysis treatment, and were observed at the
GCRC until stable, upon which they were discharged.
Analytic procedures
Blood samples were collected into Venoject tubes con-
taining 15 mg Na2EDTA (Terumo Medical Corp., Elkton,
MD, USA). A 3-mL aliquot of blood was transferred to a
tube containing EDTA and reduced glutathione with the
plasma stored at −80◦C for later measurement of plasma
epinephrine and norepinephrine concentrations by high-
performance liquid chromatography [13]. The remaining
blood was spun in a refrigerated (4◦C) centrifuge (Beck-
man Instruments, Fullerton, CA, USA) at 3000 rpm for
10 minutes and plasma was extracted and stored at −80◦C
for later analysis. Plasma glucose concentrations were de-
termined by the glucose oxidase method (Model II Glu-
cose Analyzer; Beckman Instruments).
Nutritional biochemical parameters were done at a
specialized ESRD clinical and special chemistry labora-
tory (Spectra Laboratories, San Juan, CA, USA). Serum
albumin was analyzed using bromcresol green technique.
Serum prealbumin was analyzed by an antigen-antibody
complex assay and serum transferrin was analyzed by tur-
bidimetric reading (Hitachi 717; Boehringer Mannheim,
Indianapolis, IN, USA). C-reactive protein (CRP) was
measured using nephelometric analysis at the Vanderbilt
University Medical Center Clinical Chemistry laboratory.
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Plasma c-peptide and insulin were measured by a
double-antibody radioimmunoassay (Linco Research,
Inc., St. Charles, MO, USA). Immunoreactive insulin
was determined in plasma with a double-antibody
system. Plasma aliquots for glucagon determination
were placed in tubes containing 25 kallikrein-inhibitor
units of aprotinin (Trasylol; FBA Pharmaceutical, New
York, NY, USA) and were later measured by estab-
lished radioimmunoassay with a double-antibody system
modified from the method of Morgan and Lazarow for
insulin [14]. Insulin and glucagon antisera and standards,
as well as (125I)-labeled hormones, were obtained from
RL Gingerich (Linco Research, Inc.). Clinical Assays
Gammacoat Radioimmunoassay kit (Travenol-GenTech,
Cambridge, MA, USA) was used to measure plasma cor-
tisol concentrations. Plasma insulin-like growth factor-I
(IGF-I) concentrations were determined by a radioim-
munoassay acid-extraction procedure (Nichols Institute
Diagnostics, San Juan Capistrano, CA, USA). Plasma
amino acid concentrations were determined by reverse-
phase high-performance liquid chromatography after
derivatization with phenyliosthiocynate [15]. Individual
amino acids were also placed into groups for analysis
purposes. These groups included branched chain amino
acids (BCAA–the sum of leucine, isoleucine, and va-
line); essential amino acids (EAA–the sum of arginine,
histidine, isoleucine, leucine, lysine, methionine, pheny-
lalanine, theonine, tryptophan, and valine); total amino
acids (TAA–the sum of all individual amino acids); and
nonessential amino acids (NEAA–the difference be-
tween TAA and EAA).
Plasma enrichments of (13C) leucine, (13C) ketoiso-
caproate (KIC), and (ring-2H5) phenylalanine were
determined using gas chromatography/mass spectrome-
try (GC/MS, Hewlett-Packard 5890a GC and 5970 MS;
Hewlett-Packard, San Fernando, CA, USA). Plasma
was deproteinized with 4% perchloric acid, and the
supernatant was passed over a cation exchange resin
to separate the keto and amino acids. The keto
acids were further extracted with methylene chlo-
ride and 0.5 mol/L ammonium hydroxide [16]. Af-
ter drying under nitrogen gas, keto and amino acids
fractions were derivatized [17] with N-methyl-N-(t-
butyldimethylsilyl)-trifluoroacetamide containing 1% t-
butyldimethylchlorosilane (MtBSTFA + 1% t-BDMCS;
Regis Technologies, Inc., Morton Grove, IL, USA). The
derivatized samples were then analyzed with GC/MS for
plasma leucine, phenylalanine, and KIC enrichments us-
ing selected ion monitoring. The major fragments ana-
lyzed for the tBDMCS derivative of KIC and 13C-KIC
were the (M-57) ion fragments 301 m/z and 302 m/z,
respectively. The enrichment was quantified in plasma
as the ratio of 13C-KIC:KIC (ion abundance of 301/302
m/z). Enrichment measurements were made in duplicate,
and duplicates had a coefficient of variation <3%. Breath
13CO2 was measured by isotope ratio mass spectrometry
(Metabolic Solutions, Nashua, NH, USA) [18].
Calculations
Net skeletal muscle protein balance (synthesis-
breakdown) was determined by dilution and enrichment
of phenylalanine across the forearm as described by
Gelfand and Barrett [19]. Because phenylalanine is nei-
ther synthesized de novo, nor metabolized by skeletal
muscle, rate of appearance (Ra) of unlabeled phenylala-
nine reflects muscle protein breakdown, whereas the rate
of disappearance (Rd) of labeled phenylalanine estimates
muscle protein synthesis [19]. Phenylalanine Rd was cal-
culated by multiplying the fractional extraction of the
labeled phenylalanine (based on plasma arterial and ve-
nous phenylalanine enrichments and concentrations) by
the arterial phenylalanine concentration and normalized
to forearm blood flow measured by plethysmography (ex-
pressed as 100 mL/min). Net phenylalanine Ra was calcu-
lated by subtracting the net AV balance of phenylalanine
across the extremity from the phenylalanine Rd [19, 20].
Rates of skeletal muscle protein breakdown and net syn-
thesis were determined from the phenylalanine Rd and
Ra, assuming that 3.8% of skeletal muscle protein is com-
posed of phenylalanine.
The steady-state rates of total whole-body leucine Ra
were calculated by dividing the (13C)leucine infusion rate
by the plasma (13C)KIC enrichment [20]. Plasma KIC
provides a better estimate of intracellular leucine enrich-
ment than does plasma leucine enrichment due to the fact
that KIC is derived from intracellular leucine metabolism
[20]. Steady-state conditions for KIC, phenylalanine
(Fig. 2), and CO2 (Fig. 3) enrichments were achieved as
evidenced by slopes within each phase not significantly
different than zero. Breath 13CO2 production was deter-
mined by multiplying the total CO2 production rate by
the breath 13CO2 enrichment [20]. The rate of whole-
body leucine oxidation was calculated by dividing breath
13CO2 production by 0.8 (correction factor for the re-
tention of 13CO2 in the bicarbonate pool) [21] and by
the plasma KIC enrichment. The leucine Rd, an estimate
of whole-body protein synthesis, was determined indi-
rectly by subtracting leucine oxidation from total leucine
Rd. Rates of whole-body protein breakdown, amino acid
oxidation, and protein synthesis were calculated from
the endogenous leucine Ra, the leucine oxidation rate,
and the nonoxidative leucine Rd, respectively, assum-
ing that 7.8% of whole-body protein is composed of
leucine [22].
Rates of whole-body amino acid, carbohydrate, and
lipid oxidation were determined from indirect calorime-
try in combination with the leucine oxidation data. The
energy expended due to amino acid oxidation was sub-
tracted from the total energy expenditure (TEE), and
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Fig. 2. Plasma enrichment of expired CO2 at study time points.
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Fig. 3. Plasma enrichment of KIC at study time points.
the net rates of carbohydrate and lipid oxidation were
calculated based on the nonprotein respiratory quotient
[23]. The assumptions and limitations of calculating net
substrate oxidation based on indirect calorimetry mea-
surements have been previously reviewed [23].
Statistical analysis
All values of each variable measured during the sam-
pling period were averaged for comparisons. Values pre-
sented in the text and figures are mean ± SEM. For com-
parisons between the matched groups (DM vs. non-DM),
a paired t test was used for parametric distribution and
Wilcoxon signed-rank test for nonparametric distribu-
tion. The statistical software package SPSS 12.0 (Chicago,
IL, USA) was used for analyses, and two-sided P values of
less than 0.05 were required to reject the null hypothesis
of no difference between the means.
Table 2. Metabolic hormones and glucose balance
DM Non-DM
Insulin lU/mL 25.3 ± 10.3 7.3 ± 1.0a
Glucagon ng/L 136 ± 15 142 ± 13
Growth hormone ng/mL 1.9 ± 1.1 0.6 ± 0.2
IGF-I ng/mL 273 ± 25 243 ± 39
Cortisol lg/dL 15.3 ± 2.3 14.9 ± 2.4
Epinephrine pg/mL 45 ± 7 61 ± 16
Norepinephrine pg/mL 228 ± 18 314 ± 57
Abbreviations are: IGF-I, insulin-like growth factor-1; FM, forearm muscle.
Values reported as mean ± SEM.
aDenotes significant difference vs. DM.
RESULTS
Demographics, body composition, and laboratory values
Table 1 depicts demographic characteristics, body com-
position, and baseline laboratory values of the study pop-
ulation. Subjects were well-matched for age, gender, and
race. As expected, body weight and fat mass were sig-
nificantly higher in patients with T2DM. Markers of nu-
tritional and inflammatory statuses were not significantly
different between patient groups. Both groups had less
than adequate values for serum biomarkers of nutritional
status. Glucose levels were significantly higher in pa-
tients with T2DM compared to non-DM CHD patients
(113 ± 16 mg/dL vs. 71 ± 2 mg/dL, P < 0.05). Diabetic
patients had on average HbA1C concentrations of 9.5 ±
1.0%. C-peptide concentrations were 4.0 ± 0.7 ng/mL
and 6.6 ± 3.2 ng/mL, in DM and non-DM patients, re-
spectively, P = NS. HOMA-R was significantly higher in
DM patients (2.92 ± 0.13 vs. 1.38 ± 0.17, P = 0.034)
Metabolic parameters
Table 2 shows the results for plasma metabolic hor-
mones in the 2 study groups. Whereas insulin concentra-
tions were significantly higher in T2DM patients com-
pared with non-DM CHD patients (25.3 ± 10.3 vs.
7.3±1.0 uU/mL, P <0.05), the other metabolic hormones
did not show statistically significant differences between
the 2 groups. Glucagon and cortisol levels were higher in
both study groups compared to values in healthy subjects
(data comparison not shown).
Plasma amino acids
The arterial plasma amino acid (AA) concentrations
during the studies are graphed in Figure 4 by groups
(Total AA–TAA, Nonessential AA–NEAA, Essential
AA–EAA, Branched chain AA–BCAA). In patients
with T2DM, the plasma concentrations of EAA and
BCAA were significantly higher than in non-DM pa-
tients. Specifically, EAA concentrations were 855 ± 26
lmol/L and 714 ± 50 lmol/L, and BCAA concentrations
were 371 ± 14 lmol/L and 281 ± 20 lmol/L, for DM
and non-DM patients, respectively (P < 0.05 for both
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Fig. 4. Plasma amino acids concentrations
comparing DM () with non-DM () pa-
tients. TAA, amino acids; EAA, essential
amino acids; NEAA, nonessential amino
acids; BCAA, branched-chain amino acids. ∗
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comparisons). Plasma concentrations of all 3 individual
BCAA amino acids were higher in patients with T2DM
but only statistically significantly higher for isoleucine
(isoleucine: 63.1 ± 9.8 vs. 39.7 ± 3.8 lmol/L, P < 0.05;
leucine: 136.0 ± 4.2 vs. 104.6 ± 11.7 lmol/L, and valine:
172.3 ± 13.5 vs. 136.3 ± 9.4 lmol/L, for DM vs. non-DM,
respectively).
Forearm muscle protein metabolism
The results for forearm muscle protein metabolism
components are included in Figure 5. Forearm muscle
protein breakdown was numerically higher (83%) in
CHD patients with T2DM compared to those without
DM (P = 0.144). Forearm muscle protein synthesis was
only 19% higher (P = NS) in DM compared to non-DM.
The net protein balance across the forearm was signifi-
cantly more negative (reflecting more net muscle protein
loss) in T2DM patients compared to patients without DM
(−59 ± 4 lg/100 mL/min vs. −9 ± 6 lg/100 mL/min, P <
0.05).
Whole-body protein metabolism
Figure 6 depicts the results for whole body protein
metabolism components expressed per fat-free mass
(FFM). Chronic hemodialysis patients with T2DM were
in an overall higher protein turnover state in the whole-
body compartment when compared to non-DM CHD
patients, although the differences did not reach statis-
tical significance. Specifically, whole-body protein syn-
thesis was 20% higher in patients with T2DM patients
compared to those without diabetes. Whole-body pro-
tein breakdown was 14% higher in DM versus non-DM
patients (Fig. 6). The net whole-body protein balance, a
reflection of leucine oxidation, was not different between
DM and non-DM subjects (−0.62 ± 0.19 and −0.69 ± 0.07
mg/kg FFM/min, respectively, P = NS).
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Energy metabolism and substrate oxidation
Table 3 shows the components of energy metabolism
and substrate oxidation. Unadjusted resting energy ex-
penditure (REE) was significantly higher in patients
with T2DM compared with non-DM patients (67.2 ±
4.0 kcal/hr vs. 60.3 ± 5.1 kcal/hr, P < 0.05). This signif-
icant difference disappeared after adjusting the values
for FFM, although it still remained numerically higher in
DM patients (1.46 ± 0.08 kcal/kg FFM/hr vs. 1.29 ± 0.07
kcal/kg FFM/hr, P = NS). The proportion of calories com-
ing from carbohydrate oxidation was significantly lower
in diabetics (40 ± 10% vs. 53 ± 3%, P < 0.05). Conse-
quently, more energy was derived from lipid oxidation
in DM compared to non-DM patients (50 ± 10% vs.
35 ± 5%, P < 0.05). Finally, there was also a small, but sig-
nificantly, higher portion of calories coming from protein
oxidation in non-DM CHD patients compared to DM
CHD patients (12 ± 3% vs. 10 ± 1%, respectively, P <
0.05).
DISCUSSION
Body protein loss and muscle wasting are highly preva-
lent and are associated with increased morbidity and mor-
tality in CHD patients [1]. The presence of DM in CHD
patients is known to increase the risk of developing pro-
tein depletion and loss of lean body mass [3]. In a recent
analysis of 142 ESRD patients starting renal replacement
therapy, we found that presence of DM is the strongest
independent predictor of loss of lean body mass over 12
months (Pupim et al, in press, Kidney Int 2005). In the
current study, we further provide evidence that CHD pa-
tients with T2DM have increased muscle protein break-
down, a mechanistic explanation for the high prevalence
of protein depletion and muscle wasting in this patient
population.
Table 3. Components of energy metabolism and substrate oxidation
DM Non-DM
Energy expenditure kcal/hr 67.2 ± 4.0 60.3 ± 5.1a
Energy expenditure kcal/kg FFM/hr 1.46 ± 0.08 1.29 ± 0.07
Respiratory quotient 0.83 ± 0.03 0.86 ± 0.01a
Amino acid oxidation 10 ± 1 12 ± 3a
% of energy expenditure
Carbohydrate oxidation 40 ± 10 53 ± 3a
% of energy expenditure
Lipid oxidation 50 ± 10 35 ± 5a
% of energy expenditure
Abbreviations are: BW, body weight, FFM, fat-free mass. Values reported as
mean ± SEM.
aDenotes significant difference vs. DM.
The results presented herein are consistent with in vitro
data and animal studies examining muscle protein home-
ostasis in catabolic states such as diabetes and metabolic
acidosis, and further extends these findings to CHD pa-
tients with T2DM, an observation not previously re-
ported [24–26]. Mitch et al have elegantly shown that in
insulin-deprived animals, muscle protein breakdown is
significantly increased and that this process is mediated
by the proteasome-ubiquitin pathway. They have also
recently reported that the modulation of phosphatidyli-
nositol 3-kinase is a rate-limiting step in this process, all
suggesting that a critical role may exist for insulin resis-
tance as the primary mediator of the accelerated protein
breakdown in CHD patients [24].
Indeed, a plethora of research has clearly demon-
strated insulin’s role as an anabolic hormone, both at
skeletal muscle and whole-body levels. Insulin depriva-
tion elevates protein breakdown, while insulin eleva-
tion blunts protein breakdown, and insulin interacts with
amino acid availability to regulate protein synthesis [27].
In type 1 DM patients, the anabolic effects of insulin on
protein homeostasis appear to be defective [4] and, thus,
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it is reasonable to expect similar defects under conditions
of insulin resistance.
However, similar studies examining insulin-mediated
protein metabolism are less clear in patients with T2DM
and nonexistent in CHD patients with DM. Several in-
vestigators have demonstrated a discrepancy between
resistance to insulin-mediated glucose versus protein
homeostasis in T2DM patients [9, 11, 28, 29]. Biolo
et al examined protein metabolism in 8 non–insulin-
dependent T2DM without CHD compared to 6 healthy
subjects and found no differences in protein turnover in
fasting or fed state between the 2 groups [10]. Luzi et al
found no difference in protein turnover changes in re-
sponse to euglycemic insulin clamp, with and without hy-
peraminoacidemia, in 6 non–insulin-dependent DM and
7 healthy subjects [9]. However, the fact that muscle pro-
tein synthesis does not appear to be responsive to insulin
treatment in T2DM patients and protein breakdown was
not different at basal in T2DM patients in spite of 4-fold
greater insulin concentrations suggests that anomalies in
protein homeostasis may exist in T2DM.
Data from the present study demonstrate that protein
breakdown is increased in CHD patients with T2DM who
presented with significantly higher insulin resistance as
assessed by HOMA-R index. This suggests that either
the effects of insulin resistance/deficiency are additive
to those of uremia-related factors or vice versa. Specifi-
cally, uremia per se may further substantiate the rate of
increased muscle protein breakdown, primarily by wors-
ening the level of insulin resistance [24–26]. While a
comparative analysis of protein homeostasis in T2DM
patients without renal disease would provide the appro-
priate answer to this question, such an experiment was
not the primary goal of this particular study and should be
explored with further research, which would allow us to
delineate these various mechanisms, especially to better
understand the degree of insulin resistance and to con-
trol glycemic and insulinemic levels by using more precise
techniques such as euglycemic hyperinsulinemic clamp.
Nevertheless, the data presented herein are important
because they demonstrate accelerated rate of proteolysis
by muscle tissues as a mechanism for enhanced loss of
protein stores in CHD patients with T2DM.
In addition to insulin resistance, there are several other
potential factors that may lead to accelerated muscle pro-
tein breakdown in DM CHD patients. A recent study
by Cano et al [3] suggested that commonly recognizable
causes of protein depletion, such as inadequate dialy-
sis dose and metabolic acidosis, are not in effect in this
process. In addition, diabetic gastroparesis, which could
lead to poor nutritional state, is more likely to affect
(decrease) meal-related protein synthesis. In the present
study, dietary protein intake and, more importantly, pro-
tein synthesis rates were similar in DM and non-DM pa-
tients, suggesting that diabetic gastroparesis is an unlikely
cause for the differences observed between study groups.
Glucagon, glucocorticoids, and catecholamines are coun-
terregulatory hormones whose metabolic role may also
counteract protein anabolism [30]. Studies have specu-
lated that these hormones contribute further to already
existing insulin resistance [31]. The separate effects of
each of these hormones on muscle proteins under stress-
ful situations are not well-defined because they are gen-
erally concomitantly altered in such conditions. Nonethe-
less, in the present study there were no significant differ-
ences in these hormones between the study groups. With
regards to energy expenditure, in the present study, REE
was significantly higher in CHD patients with T2DM
compared to non-DM but the statistical significance dis-
appeared after adjusting for FFM, although the numerical
difference remained.
An interesting finding in this study was that the differ-
ence between the diabetic and nondiabetic groups was
only present for the muscle compartment but was not sig-
nificant for whole-body protein turnover. While skeletal
muscle comprises approximately 50% of the whole-body
protein pool, and skeletal muscle breakdown changes
were in a similar direction as the whole-body protein pool,
the possibility of changes in protein breakdown by other
tissues needs to be raised [32]. One potential speculation
is that DM patients may have a compensatory decrease
in breakdown of proteins other than the skeletal mus-
cle proteins. Conversely, there may be increases in the
synthetic rates of acute phase proteins in the liver [33].
Future studies examining synthetic and catabolic rates of
individual proteins representative of specific metabolic
pathways may provide insight into this finding.
It should be noted that our study population for both
groups were stable and specifically did not have evidence
of inflammation, as estimated by CRP serum concentra-
tions (except for 1 T2DM patient who had serum CRP
of 3.7 mg/dL). This allows us to exclude metabolic ab-
normalities like inflammation that may influence protein
homeostasis when interpreting our results. Similar stud-
ies in patient populations with more diverse nutritional
and inflammatory status would be useful to further exam-
ine the factors that predispose CHD patients to protein
depletion. Furthermore, the importance of the difference
in body fat between the DM and non-DM groups cannot
be evaluated from the design of the present study. Finally,
while the techniques used in this study are associated with
a margin of error, these are small and the techniques are
well accepted and validated. In addition, we have used
these techniques in several study populations and have
found them to be reliable and reproducible.
CONCLUSION
CHD patients with T2DM have significantly increased
skeletal muscle protein breakdown as compared to
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matched non-DM CHD patients. There is no significant
difference in protein synthesis rates, leading to net mus-
cle protein breakdown with amino acid release to the
bloodstream. These findings could provide a mechanis-
tic explanation as to why CHD patients with T2DM are
more prone to protein depletion than CHD patients with-
out diabetes. Further studies with controlled insulin and
glucose concentrations are warranted to further define
the mechanisms of impaired protein metabolism in CHD
patients with T2DM.
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